Humacyte, Inc. (NASDAQ:HUMA) Receives $7.71 Consensus Price Target from Analysts

Humacyte, Inc. (NASDAQ:HUMA) has been assigned an average rating of “Moderate Buy” from the eight analysts that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation and seven have assigned a buy recommendation to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $7.7143.

HUMA has been the subject of a number of research reports. Benchmark decreased their price target on shares of Humacyte from $11.00 to $10.00 and set a “buy” rating for the company in a research report on Wednesday, January 21st. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Humacyte in a research report on Friday, April 10th. Wall Street Zen cut shares of Humacyte from a “sell” rating to a “strong sell” rating in a research report on Saturday, April 11th. D. Boral Capital reiterated a “buy” rating and issued a $25.00 price objective on shares of Humacyte in a report on Tuesday, April 28th. Finally, BTIG Research reiterated a “buy” rating and issued a $3.00 price objective on shares of Humacyte in a report on Tuesday, April 28th.

Humacyte Stock Up 9.8%

Shares of Humacyte stock opened at $1.08 on Friday. The company has a fifty day moving average price of $0.87 and a 200 day moving average price of $1.09. The company has a current ratio of 3.69, a quick ratio of 2.95 and a debt-to-equity ratio of 20.08. Humacyte has a twelve month low of $0.55 and a twelve month high of $2.93. The stock has a market cap of $239.78 million, a price-to-earnings ratio of -5.40 and a beta of 2.31.

Humacyte (NASDAQ:HUMA) last announced its quarterly earnings results on Friday, March 27th. The company reported ($0.13) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.13). Humacyte had a negative net margin of 1,998.87% and a negative return on equity of 990.48%. The firm had revenue of $0.47 million during the quarter, compared to analysts’ expectations of $1.35 million. Equities research analysts forecast that Humacyte will post -0.39 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Humacyte

A number of institutional investors have recently added to or reduced their stakes in HUMA. Marshall Wace LLP lifted its holdings in Humacyte by 5,308.2% in the 2nd quarter. Marshall Wace LLP now owns 2,639,194 shares of the company’s stock worth $5,516,000 after buying an additional 2,590,394 shares in the last quarter. Millennium Management LLC lifted its holdings in Humacyte by 129.5% in the 4th quarter. Millennium Management LLC now owns 2,631,990 shares of the company’s stock worth $2,528,000 after buying an additional 1,485,152 shares in the last quarter. UBS Group AG lifted its holdings in Humacyte by 48.8% in the 4th quarter. UBS Group AG now owns 2,978,610 shares of the company’s stock worth $2,862,000 after buying an additional 976,275 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Humacyte by 33.4% in the 2nd quarter. Geode Capital Management LLC now owns 2,948,508 shares of the company’s stock worth $6,163,000 after buying an additional 738,142 shares in the last quarter. Finally, Barclays PLC lifted its holdings in Humacyte by 298.7% in the 4th quarter. Barclays PLC now owns 729,469 shares of the company’s stock worth $701,000 after buying an additional 546,491 shares in the last quarter. Institutional investors and hedge funds own 44.71% of the company’s stock.

About Humacyte

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.